Perrigo, Hikma, Mallinckrodt Bid for Boehringer’s Roxane Labs

Source: Bloomberg

Jul 01, 2015

Dublin-based drugmakers Mallinckrodt and Perrigo as well as London-based Hikma Pharma are all potential buyers for Boehringer Ingelheim’s Roxane Labs business in the U.S., according to Bloomberg sources.

The generic pharmaceutical unit could sell for a potential $2.2 billion -- or the German drugmaker may still choose to keep the asset.

Sources say a decision could be made within weeks.

According to Bidness Etc,  a Perrigo-Roxane merger would create an additional hurdle in Mylan’s quest to buy Perrigo, as the acquisition would enable Perrigo to expand its platform into generics while remaining a standalone entity. This would be good news for Teva, as Mylan desperately needs the Perrigo merger to defend against Teva's unsolicited $82 per share takeover offer.

Read the Bloomberg article

Return to the Pharma Mfg Newsletter